Your session is about to expire
← Back to Search
Etrumadenant + Zimberelimab for Sarcoma
Study Summary
This trial will test the effectiveness of a drug combo to treat advanced dedifferentiated liposarcoma, which has come back, spread, or is unresectable.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have active cancer spread to my brain or spinal cord.I am currently being treated for another cancer that is not related.I have been treated with PD-1 or PD-L1 inhibitors before.I have HIV with specific CD4+ T-cell counts or opportunistic infections.My condition is an advanced liposarcoma that cannot be surgically removed.I have had an active tuberculosis infection in the past.I have been treated with drugs targeting the adenosine pathway.I have an active hepatitis B or C infection.I am fully active or able to carry out light work.My blood tests for organ function are within normal ranges.I cannot take pills due to my stomach or intestinal problems.My current medications do not interact with etrumadenant.I have had previous treatments for my condition.I am 18 years old or older.I haven't had recent cancer treatments or major surgery.I do not have any uncontrolled illnesses or heart failure symptoms in the last 6 months.My cancer came back after surgery to remove the initial tumor.I have not needed treatment for an autoimmune disease in the last 2 years.
- Group 1: Participants With Dedifferentiated Liposarcoma/DDLPS
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the U.S. Food & Drug Administration given clearance to use Participants With Dedifferentiated Liposarcoma/DDLPS?
"Although no efficacy data is available, participants with dedifferentiated liposarcoma/DDLPS were rated a 2 due to the existence of safety-related clinical evidence."
What is the geographic scope of this clinical trial's implementation?
"This trial is currently running at 7 clinical sites, that are spread out between Middletown, Montvale and Commack as well as other cities. If you choose to participate in the study it is advised to pick the most convenient location for yourself so as to reduce any transportation needs."
Are there any remaining vacancies for participants in this medical trial?
"Indeed, clinicaltrials.gov shows that the study is currently recruiting. It was posted on May 23rd 2023 and updated then too; it requires 25 patients to volunteer from 7 sites."
How many volunteers are being enlisted for this clinical experiment?
"Affirmative. Clinicaltrials.gov indicates that this clinical trial is actively seeking 25 participants from seven different clinics since its inception on May 23rd, 2023 and most recent update of the same date."
Share this study with friends
Copy Link
Messenger